Ethyl-β-D-N-acetylgalactosamin | 6082-23-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Ethyl-β-D-N-acetylgalactosamin
• 英文别名: N-(O¹-ethyl-β-D-galactopyranose-2-yl)-acetamide；N-(O¹-Aethyl-β-D-galactopyranose-2-yl)-acetamid；N-[(2R,3R,4R,5R,6R)-2-ethoxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• CAS: 6082-23-1
• 化学式: C₁₀H₁₉NO₆
• 分子量: 249.264
• InChiKey: KRABAWXNIPSDEF-HOTMZDKISA-N

物化性质

• 熔点：
  220-222 °C(Solv: ethanol (64-17-5); ethyl ether (60-29-7))
• 沸点：
  525.6±50.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(乙酰氨基)-2-脱氧-alpha-D-吡喃半乳糖基氯化物 3,4,6-三乙酸酯 在 甲醇 、 氯仿 、 barium methoxide 、 sodium sulfate 、 silver(l) oxide 作用下， 生成 Ethyl-β-D-N-acetylgalactosamin
  参考文献：
  名称：

  Acetohalogeno Derivatives and Glycosides of D-Galactosamine¹

  摘要：

  DOI：

  10.1021/ja01556a040

文献信息

• TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9
  申请人：Pfizer Inc.

  公开号：EP3373979A1

  公开（公告）日：2018-09-19
• BLOCK COPOLYMERS
  申请人：GENEVANT SCIENCES GMBH

  公开号：US20210023235A1

  公开（公告）日：2021-01-28

  Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
• US9867885B2
  申请人：——

  公开号：US9867885B2

  公开（公告）日：2018-01-16
• [EN] TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9<br/>[FR] INGÉNIERIE GÉNOMIQUE SPÉCIFIQUE DE TISSUS UTILISANT LE CRISPR-CAS9
  申请人：PFIZER

  公开号：WO2017083368A1

  公开（公告）日：2017-05-18

  The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
• [EN] OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSITIONS DE CONJUGUÉS D'OLIGONUCLÉOTIDES ET MÉTHODES D'UTILISATION
  申请人：MINA THERAPEUTICS LTD

  公开号：WO2021032777A1

  公开（公告）日：2021-02-25

  The disclosure relates to GalNAc moieties comprising at least one GalNAc monomer. The disclosure also relates to GalNAc-oligonucleotide conjugates comprising GalNAc moieties and oligonucleotides, e.g., saRNAs or siRNAs useful in regulating the expression of a target gene. Methods of using the GalNAc- oligonucleotide conjugates are also provided.